
Elizabeth Fabre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2991185/publications.pdf Version: 2024-02-01



FUZARETH FARDE

#	Article	IF	CITATIONS
1	Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. PLoS Medicine, 2016, 13, e1002199.	8.4	76
2	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers, 2020, 12, 473.	3.7	72
3	Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA. Clinical Chemistry, 2016, 62, 1492-1503.	3.2	68
4	Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. British Journal of Cancer, 2019, 121, 405-416.	6.4	63
5	Selective EGF-Receptor Inhibition inÂCD4+ÂTÂCells Induces Anergy andÂLimitsÂAtherosclerosis. Journal of the American College of Cardiology, 2018, 71, 160-172.	2.8	54
6	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. Cancer Treatment Reviews, 2018, 65, 54-64.	7.7	51
7	CXCR6 deficiency impairs cancer vaccine efficacy and CD8 ⁺ resident memory T-cell recruitment in head and neck and lung tumors. , 2021, 9, e001948.		41
8	Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non–Small-Cell Lung Cancer. Journal of Molecular Diagnostics, 2018, 20, 550-564.	2.8	30
9	Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. Lung Cancer, 2021, 155, 114-119.	2.0	12
10	Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer. BMC Cancer, 2022, 22, 529.	2.6	11
11	EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. Cancers, 2021, 13, 5132.	3.7	9
12	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. EBioMedicine, 2021, 73, 103630.	6.1	6
13	Longer survival in patients with metastatic uterine leiomyosarcoma treated with trabectedin: A case report. Molecular and Clinical Oncology, 2019, 10, 387-390.	1.0	4
14	Evolution of induction chemotherapy for nonâ€small cell lung cancer over the last 30 years: A surgical appraisal. Thoracic Cancer, 2015, 6, 731-740.	1.9	3
15	N2 involvement in lung cancer: the DanaÃ ⁻ des' barrel. European Journal of Cardio-thoracic Surgery, 2015, 48, 176.1-176.	1.4	2